CN(C=O)C.Br[CH2:7][CH2:8][NH:9][C:10]([C:12]1[CH:13]=[C:14]([CH2:18][CH2:19][CH:20]2[CH2:25][CH2:24][N:23]([C:26]([O:28][C:29]3[CH:30]=[N:31][CH:32]=[C:33]([CH:38]=3)[C:34]([O:36][CH3:37])=[O:35])=[O:27])[CH2:22][CH2:21]2)[CH:15]=[CH:16][CH:17]=1)=[O:11].C(=O)([O-])[O-].[K+].[K+].[I-].[K+]>CCOC(C)=O>[N:9]1([C:10]([C:12]2[CH:13]=[C:14]([CH2:18][CH2:19][CH:20]3[CH2:25][CH2:24][N:23]([C:26]([O:28][C:29]4[CH:30]=[N:31][CH:32]=[C:33]([CH:38]=4)[C:34]([O:36][CH3:37])=[O:35])=[O:27])[CH2:22][CH2:21]3)[CH:15]=[CH:16][CH:17]=2)=[O:11])[CH2:7][CH2:8]1A DMF (10 ml) suspension of methyl 5-[{(4-[2-(3-{[(2-bromoethyl)amino]carbonyl}phenyl)ethyl]piperidin-1-yl}carbonyl)oxy]nicotinate (750 mg), potassium carbonate (300 mg) and potassium iodide (361 mg) was stirred at 80° C. for 1 hour. The reaction liquid was left cooled, then EtOAc was added thereto, washed with aqueous saturated sodium hydrogencarbonate solution and saturated brine in that order, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform:methanol=20:1 (v/v)) to obtain methyl 5-{[(4-{2-[3-(aziridin-1-ylcarbonyl)phenyl]ethyl}piperidin-1-yl)carbonyl]oxy}nicotinate (630 mg) as a colorless oil.
Loading…